Innate Pharma SA Interest Expense
Innate Pharma SA (IPHA) reported Interest Expense of EUR 440.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Expense Statement
ifrs-full:InterestExpense · last filed 2026-04-01
| Period end | Interest Expense 6 month | Interest Expense 12 month |
|---|---|---|
| 2025-12-31 | 440.00K EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | 229.00K EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | 566.00K EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | 300.00K EUR 6-K · filed 2025-09-17 | |
| 2023-12-31 | 640.00K EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 324.00K EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | 288.00K EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 194.00K EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | 312.00K EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | 160.00K EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | 341.00K EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | 173.00K EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | 204.00K EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 102.00K EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 113.00K EUR 20-F · filed 2020-04-24 |